NASDAQ: AMLXAmylyx Pharmaceuticals Inc Stock
$1.83+0.00 (+0%)
Updated May 17, 2024
AMLX Price
$1.83
Fair Value Price
N/A
Market Cap
$124.45M
52 Week Low
$1.70
52 Week High
$27.98
P/E
-1.76x
P/B
0.38x
P/S
0.48x
PEG
N/A
Dividend Yield
N/A
Revenue
$398.00M
Earnings
-$71.10M
Gross Margin
65.7%
Operating Margin
-16.5%
Profit Margin
-17.9%
Debt to Equity
0.29
Operating Cash Flow
$17M
Beta
1.18
Next Earnings
Jun 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A
AMLX Overview
Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, for the treatment of ALS. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, MA.
Zen Score
–
Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AMLX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AMLX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AMLX is good value based on its book value relative to its share price (0.38x), compared to the US Biotechnology industry average (6.01x)
P/B vs Industry Valuation
AMLX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more AMLX due diligence checks available for Premium users.
Be the first to know about important AMLX news, forecast changes, insider trades & much more!
AMLX News
Valuation
AMLX fair value
Fair Value of AMLX stock based on Discounted Cash Flow (DCF)
Price
$1.83
Fair Value
-$14.42
Undervalued by
112.69%
AMLX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AMLX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.76x
Industry
8.47x
Market
30.97x
AMLX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.38x
Industry
6.01x
AMLX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AMLX's financial health
Profit margin
Revenue
$88.6M
Net Income
-$118.8M
Profit Margin
-134%
AMLX's Earnings (EBIT) of -$65.66M... subscribe to Premium to read more.
Interest Coverage Financials
AMLX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$417.5M
Liabilities
$93.0M
Debt to equity
0.29
AMLX's short-term assets ($410.53M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AMLX's short-term assets ($410.53M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AMLX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$489.0k
Investing
$819.0k
Financing
$131.0k
AMLX's operating cash flow ($16.50M)... subscribe to Premium to read more.
Debt Coverage Financials
AMLX vs Biotech Stocks
Amylyx Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.